194 related articles for article (PubMed ID: 27283899)
41. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
42. LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1.
Ai B; Kong X; Wang X; Zhang K; Yang X; Zhai J; Gao R; Qi Y; Wang J; Wang Z; Fang Y
Cell Death Dis; 2019 Jun; 10(7):502. PubMed ID: 31243265
[TBL] [Abstract][Full Text] [Related]
43. β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
Xu J; Chen Y; Huo D; Khramtsov A; Khramtsova G; Zhang C; Goss KH; Olopade OI
Mol Carcinog; 2016 May; 55(5):431-9. PubMed ID: 25663530
[TBL] [Abstract][Full Text] [Related]
44. NOTCH4 is a potential therapeutic target for triple-negative breast cancer.
Nagamatsu I; Onishi H; Matsushita S; Kubo M; Kai M; Imaizumi A; Nakano K; Hattori M; Oda Y; Tanaka M; Katano M
Anticancer Res; 2014 Jan; 34(1):69-80. PubMed ID: 24403446
[TBL] [Abstract][Full Text] [Related]
45. UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
Li J; Liang Y; Zhou S; Chen J; Wu C
Breast Cancer Res; 2024 Mar; 26(1):44. PubMed ID: 38468288
[TBL] [Abstract][Full Text] [Related]
46. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
47. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
[TBL] [Abstract][Full Text] [Related]
48. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
49. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
[TBL] [Abstract][Full Text] [Related]
50. Antibiotic Tetrocarcin-A Down-regulates JAM-A, IAPs and Induces Apoptosis in Triple-negative Breast Cancer Models.
Vellanki SH; Cruz RGB; Richards CE; Smith YE; Hudson L; Jahns H; Hopkins AM
Anticancer Res; 2019 Mar; 39(3):1197-1204. PubMed ID: 30842150
[TBL] [Abstract][Full Text] [Related]
51. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
52. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
[TBL] [Abstract][Full Text] [Related]
53. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer.
Jian Y; Huang X; Fang L; Wang M; Liu Q; Xu H; Kong L; Chen X; Ouyang Y; Wang X; Wei W; Song L
J Exp Clin Cancer Res; 2021 Feb; 40(1):56. PubMed ID: 33541412
[TBL] [Abstract][Full Text] [Related]
54. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
55. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
Lee KM; Giltnane JM; Balko JM; Schwarz LJ; Guerrero-Zotano AL; Hutchinson KE; Nixon MJ; Estrada MV; Sánchez V; Sanders ME; Lee T; Gómez H; Lluch A; Pérez-Fidalgo JA; Wolf MM; Andrejeva G; Rathmell JC; Fesik SW; Arteaga CL
Cell Metab; 2017 Oct; 26(4):633-647.e7. PubMed ID: 28978427
[TBL] [Abstract][Full Text] [Related]
56. GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancer.
Peng L; Song Z; Chen D; Linghu R; Wang Y; Zhang X; Kou X; Yang J; Jiao S
Biomed Pharmacother; 2016 Dec; 84():1568-1574. PubMed ID: 27829549
[TBL] [Abstract][Full Text] [Related]
57. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
58. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
59. Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma.
Hagenbuchner J; Rupp M; Salvador C; Meister B; Kiechl-Kohlendorfer U; Müller T; Geiger K; Sergi C; Obexer P; Ausserlechner MJ
Oncotarget; 2016 Nov; 7(47):77591-77606. PubMed ID: 27769056
[TBL] [Abstract][Full Text] [Related]
60. Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
Bouchard G; Therriault H; Geha S; Bérubé-Lauzière Y; Bujold R; Saucier C; Paquette B
BMC Cancer; 2016 Jun; 16():361. PubMed ID: 27282478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
